Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 15, 2025
Daily News
July 15, 2025
- Asahi Kasei Sharpens Acquisition Focus in Pharma Biz as Envarsus LOE Looms
July 15, 2025
- MSD Seeks Japan Nod for RSV Antibody Clesrovimab
July 15, 2025
- Takeda’s OX2R Agonist Makes Mark in PIII NT1 Trials, US Filing Planned in FY2025
July 15, 2025
- FDA Rejects Capricor/Nippon Shinyaku’s DMD Cell Therapy, Seeking More Data
July 15, 2025
- Eisai Launches Gout Drug Urece in China
July 15, 2025
- Japan’s Feliqs to Relocate Headquarters to US, Launch PIb for ROP Drug
July 15, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Merck Japan Joins Hands with Kawasaki City Incubator to Support Startups
July 15, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…